Forbion Capital Partners is a private equity and venture capital firm for making investments in buyouts.
Business Model:
Revenue: $0
Employees: 2-10
Address: PO Box 5187
City: Naarden
State: flevoland
Zip: 1410
Country: NL
Forbion Capital Partners is a Netherlands-based venture capital firm focused on investing in life sciences companies in drug development as well as MedTech companies addressing high medical needs. Forbion&s;s investment team of nine investment professionals has built an impressive performance track record since the late nineties with successful investments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda, Fovea and PanGenetics. Current assets under management exceed €400m ($500m), split between three active funds. Finally, Forbion co-manages BioGeneration Ventures, an early stage fund focused on academic spin-outs and seed investments in the Netherlands.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
3/2015 | Insmed | Post-IPO Equity | - |
3/2023 | Seamless Therapeutics | Seed Round | 0 |
1/2021 | Complement Therapeutics | Seed Round | - |
10/2011 | Hookipa Pharma | Series A | 9.6M |
7/2017 | Exosome Diagnostics | Series C | 0 |
6/2022 | VectivBio | Post-IPO Equity | 0 |
1/2016 | Exosome Diagnostics | Series B | 0 |
11/2011 | CircuLite | Series D | 30M |
3/2009 | Pathway Medical Technologies | Series D | 42.5M |
11/2013 | Argos Therapeutics | Series E | 0 |
1/2021 | New Amsterdam Pharma | Series A | 0 |
6/2010 | Cytheris | Series D | 15M |
3/2010 | Promedior | Series C | 12M |
7/2005 | Xention | Series B | 13.3M |
10/2001 | Ardana Bioscience | Series A | 20M |
9/2014 | Pulmologix | Venture Round | 12.4M |
8/2007 | AM Pharma | Series C | 3.4M |
9/2011 | Amakem | Series A | 25.2M |
12/2007 | Santaris Pharma | Series C | 30M |
4/2012 | Argos Therapeutics | Series D | 0 |
3/2010 | Bluebird Bio | Series B | 35M |
3/2005 | Borean Pharma | Series A | 0 |
12/2007 | Fovea Pharmaceuticals | Series B | 30M |
8/2017 | Milestone Pharmaceuticals | Series C | 55M |
12/2013 | Ario Pharma | Seed Round | 3.1M |
12/2016 | Hookipa Pharma | Series B | 10.7M |
3/2023 | Noema Pharma | Series B | 0 |
7/2013 | UniQure | Private Equity Round | 0 |
4/2023 | Complement Therapeutics | Series A | 0 |
3/2014 | Exosome Diagnostics | Series B | 0 |
4/2007 | CircuLite | Series B | 5M |
1/2010 | CircuLite | Series C | 32.5M |
9/2009 | arGEN-X | Series A | 13.6M |
11/2021 | Prilenia | Series B | 0 |
8/2022 | F2G | Private Equity Round | 0 |
1/2011 | PneumRx | Venture Round | 0 |
3/2008 | PanGenetics | Series C | 35.1M |
10/2018 | Gotham Therapeutics | Series A | 54M |
4/2013 | Allecra Therapeutics | Series A | 19.6M |
2/2017 | Prexton Therapeutics | Series B | 31.1M |
6/2015 | Realeve | Series D | 43.2M |
6/2016 | Allecra Therapeutics | Series B | 24.8M |
6/2019 | SANIFIT | Series D | 0 |
11/2003 | Roche Glycart | Series A | 13.6M |
5/2012 | Mitralign | Series D | 0 |
9/2015 | SANIFIT | Series C | 0 |
9/2017 | Replimune Group | Series B | 55M |
5/2003 | Acorda Therapeutics | Series B | 55.3M |
2/2010 | arGEN-X | Series A | 4.5M |
7/2019 | AM Pharma | Series F | 130.1M |
11/2022 | New Amsterdam Pharma | Post-IPO Equity | 0 |
7/2021 | NeRRe Therapeutics | Series B | 0 |
9/2022 | Pheon Therapeutics | Series A | 0 |
7/2012 | Bluebird Bio | Series D | 0 |
3/2003 | Acadia Pharmaceuticals Inc. | Series F | 25M |
11/2014 | Curetis | Series B | 0 |
9/2015 | Replimune Group | Series A | 30M |
12/2002 | Transave | Series B | - |
10/2022 | Inversago Pharma | Series C | 0 |
4/2019 | Dyne Therapeutics | Series A | 50M |
9/2015 | Exosome Diagnostics | Series B | 0 |
2/2011 | CellNovo | Series B | 48.3M |
2/2013 | Dezima Pharma | Venture Round | 18.6M |
3/2021 | Oxular | Series B | 37M |
1/2021 | CoviCept Therapeutics | Seed Round | 2.3M |
1/2020 | NorthSea Therapeutics | Series B | 40M |
9/2005 | Bioceros | Private Equity Round | - |
6/2020 | Prilenia | Series A | 62.5M |
4/2018 | Enterprise Therapeutics | Series B | 41.3M |
3/2021 | Amphista Therapeutics | Series B | 0 |
11/2013 | Hookipa Pharma | Series B | 27M |
11/2020 | Achilles Therapeutics | Series C | 69.8M |
10/2021 | Rectify Pharmaceuticals | Series A | 0 |
9/2020 | Inversago Pharma | Series B | 0 |
8/2018 | KaNDy Therapeutics | Series C | 32.6M |
2/2016 | Akarna | Series B | 15M |
11/2011 | Oxyrane | Series D | 26.5M |
7/2011 | gIcare Pharma | Series A | 7.4M |
11/2022 | CatalYm | Series C | 0 |
12/2021 | Anaveon | Series B | 0 |
4/2011 | Bluebird Bio | Series C | 30M |
11/2020 | Catalym | Series B | 59.3M |
2/2020 | Azafaros | Series A | 27.5M |
6/2021 | VectorY | Seed Round | 0 |
10/2004 | FlowMedica | Series C | 0 |
5/2010 | Exosome Diagnostics | Series A | 20M |
12/2021 | ARMGO,Pharma,Inc. | Series B | 0 |
11/2006 | Pieris AG | Series B | 0 |
8/2009 | NovoGI | Series F | 0 |
1/2003 | Impella Cardiosystems | Venture Round | 40M |
12/2011 | arGEN-X | Series B | 43.8M |
12/2017 | Hookipa Pharma | Series C | 0 |
10/2012 | Promedior | Series D | 0 |
3/2012 | Promedior | Series D | 21.5M |
8/2016 | Catalym | Seed Round | - |
1/2017 | NeRRe Therapeutics | Series B | 28.6M |
3/2022 | Precirix | Series B | 0 |
4/2008 | Transave | Series D | 35M |
3/2020 | AM Pharma | Venture Round | 25.4M |
3/2009 | BioVex | Venture Round | 40M |
12/2021 | NorthSea Therapeutics | Series C | 0 |
10/2011 | Curetis | Series A | 13.3M |
3/2021 | Gyroscope Therapeutics | Series C | 0 |
9/2019 | Achilles Therapeutics | Series B | 120.9M |
3/2015 | Rigontec | Series A | 5.2M |
5/2023 | Dualyx | Series A | 0 |
5/2015 | Realeve | Series D | 38M |
5/2021 | Numab | Series C | 110.6M |
9/2016 | Rigontec | Series A | 16.9M |
8/2020 | Dyne Therapeutics | Series B | 115M |
10/2018 | Milestone Pharmaceuticals | Series D | 80M |
12/2017 | NorthSea Therapeutics | Series A | 29.4M |
5/2015 | Replimune Group | Seed Round | 2M |
10/2022 | VectivBio | Post-IPO Equity | 0 |
11/2018 | OMEICOS Therapeutics | Series C | 0 |
2/2022 | Complement Therapeutics | Seed Round | 5.7M |
11/2018 | Inflazome | Series B | 45.8M |
6/2012 | Santaris Pharma | Venture Round | 12M |
1/2015 | enGene | Series B | 0 |
3/2018 | Escalier Biosciences | Series B | 19M |
9/2010 | Cardoz | Series A | 17.6M |
4/2023 | Complement Therapeutics | Series A | 0 |
3/2023 | Seamless Therapeutics | Seed Round | 0 |
3/2023 | Noema Pharma | Series B | 0 |
11/2022 | New Amsterdam Pharma | Post-IPO Equity | 0 |
11/2022 | CatalYm | Series C | 0 |
10/2022 | Inversago Pharma | Series C | 0 |
10/2022 | VectivBio | Post-IPO Equity | 0 |
9/2022 | Pheon Therapeutics | Series A | 0 |
8/2022 | F2G | Private Equity Round | 0 |
6/2022 | VectivBio | Post-IPO Equity | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|